Skip to main content
Martin Gutierrez, MD, Oncology, Hackensack, NJ, Hackensack Meridian Health Hackensack University Medical Center

MartinEduardoGutierrezMD

Oncology Hackensack, NJ

Director Drug Discovery/Phase I Research Chief of Thoracic Oncology Member of GI Division

Overview of Dr. Gutierrez

As co-chief, Thoracic Oncology, and director of the Phase 1 Program, I specialize in bringing Phase 1 clinical trials to cancer patients treated at John Theurer Cancer Center. The approximately 40 Phase 1 trials currently in place are focused on immunotherapy, targeted therapies, and cell technologies such as CAR-T therapy, which engineers T-cells to target cancer.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 1993 - 1996
  • Pontifical Xavierian University
    Pontifical Xavierian UniversityClass of 1991

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2021 - 2026
  • NJ State Medical License
    NJ State Medical License 2011 - 2025
  • FL State Medical License
    FL State Medical License 2000 - 2014
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Utilization of next generation sequencing (NGS) and rates of undergenotyping in patients with metastatic colon cancer (mCC) treated at academic and community centers i... 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
  • Rates of genotyping for , , , microsatellite instability (MSI), and mismatch repair (MMR) in metastatic colon cancer patients: Gaps and implications. 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
  • Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
  • Join now to see all

Press Mentions

  • Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
    Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of CancerSeptember 5th, 2022
  • Molecular Tumor Testing Transformative, yet 'Under-Optimized'
    Molecular Tumor Testing Transformative, yet 'Under-Optimized'July 23rd, 2021
  • NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
    NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingMay 19th, 2021
  • Join now to see all

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    AmeriHealth Direct POS
    Amerihealth HMO
    AmeriHealth PPO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    First Health PPO
    GHI PPO
    Great West PPO
    Horizon BCBS Direct Access
    Horizon BCBS HMO
    Horizon BCBS POS
    Horizon BCBS PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment